Santarus Inc (SNTS)

[deniseann]

SNTS This is a re-post excerpt from post 91 (this board) by FDA Plays moderator "cccpmd666". SNTS DD:

But very justified.

For ccc's graphics and excellent presentation, revisit POST 115.

I feel Santarus, Inc. is a long play at this point, but solid enough not to lose money for you, and if you're willing to wait it out, a very lucrative play. MHO

denise.



cccpmd666 Member Profile cccpmd666 Member Level Share Tuesday, April 20, 2010 3:28:55 PM
Re: None Post # of 115
SNTS DD:
Santarus, Inc. is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by gastroenterologists, endocrinologists and other physicians. The company’s current commercial efforts are focused on ZEGERID® (omeprazole/sodium bicarbonate), which is indicated for the treatment of certain upper GI diseases and disorders, and on GLUMETZA® (metformin hydrochloride extended release tablets), which is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. Santarus is also developing two late-stage lower GI product candidates, budesonide MMX® and rifamycin SV MMX®, for the U.S. market. Budesonide MMX is being investigated in a Phase III clinical program for the induction of remission of mild or moderate active ulcerative colitis. Santarus expects to begin Phase III clinical testing of rifamycin SV MMX in patients with travelers’ diarrhea in the second quarter of 2010.


Latest 10k http://ir.santarus.com/secfiling.cfm?filingID=950123-10-20667

ZEGERID® (omeprazole/sodium bicarbonate) is the Only Immediate-Release Oral proton pump inhibitor (PPI) providing continued acid control for patients with gastroesophagael reflux disease (GERD).
ZEGERID is indicated for:
•Short-term treatment (4-8 weeks) of active duodenal ulcer

•Short-term treatment (4-8 weeks) of active benign gastric ulcer
•Heartburn and other symptoms associated with GERD

•Short-term treatment (4-8 weeks) of erosive esophagitis which has been diagnosed in endoscopy

•Maintenance of healing of erosive esophagitis (controlled studies do not extend beyond 12 months)

•Reduction of risk of upper GI bleeding in critically ill patients (powder for oral suspension only)

ZEGERID Powder for Oral Suspension 40 mg/1680 mg is the only FDA approved PPI for reduction of risk of upper GI bleeding in critically ill patients. Use beyond 14 days has not been evaluated.